Jardiance (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged
The rate of type 2 diabetes in the young has almost doubled in 16 years, but there is still not enough evidence to assess the balance of benefits versus harms of screening in youth.
By Julie Steenhuysen CHICAGO (Reuters) - A U.S. panel tasked with weighing the pros and cons of regular diabetes screening for children and adolescent.